By Colin Kellaher
Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum contagiosum infections.
Ligand on Thursday said it will invest $18 million in the combined company, which will operate as Pelthos Therapeutics, while a group led by investment firm Murchinson will chip in an additional $32 million.
Channel, a Freehold, N.J., clinical-stage biotechnology company that had a market capitalization of around $7.7 million based on Thursday's closing share price of $1.26, said its shareholders will own about 7.7% of the combined company, while Ligand will own about 55% and the other investors will own roughly 37%.
Channel shares were recently up nearly 20% at $1.50 in premarket trading.
The U.S. Food and Drug Administration in January 2024 approved Zelsuvmi as the first novel drug for the treatment of molluscum contagiosum, a highly contagious viral skin infection.
Jupiter, Fla., biopharmaceutical company Ligand last year formed Pelthos to accelerate commercialization of the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 17, 2025 07:31 ET (11:31 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.